Keytruda
Payments companies reported to CMS as associated with Keytruda. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Keytruda, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Keytruda
These are the largest totals companies reported as associated with Keytruda. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Chad Reichard | Carmel, IN | Urology | $153,034.93 |
| Solly Chedid | Pascagoula, MS | Hematology & Oncology | $137,333.42 |
| Ammar Sukari | Detroit, MI | Medical Oncology | $136,346.95 |
| Vahan Kassabian | Roswell, GA | Urology | $131,208.39 |
| Amit Mehta | Cary, NC | Hematology & Oncology | $125,281.92 |
| Krzysztof Misiukiewicz | New York, NY | Medical Oncology | $120,150.72 |
| Jolanta Baginski | Clearwater, FL | Nurse Practitioner | $118,913.88 |
| Janakiraman Subramanian | Fairfax, VA | Medical Oncology | $114,118.36 |
| Kamran Shahid | Lake Charles, LA | Hematology & Oncology | $108,689.29 |
| Nancy Dawson | Washington, DC | Medical Oncology | $100,458.64 |
Prescribed Keytruda?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.